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Abstract
Background: Many retinal degenerative diseases are caused by the loss of retinal ganglion cells (RGCs). Autosomal
dominant optic atrophy is the most common hereditary optic atrophy disease and is characterized by central vision
loss and degeneration of RGCs. Currently, there is no effective treatment for this group of diseases. However, stem
cell therapy holds great potential for replacing lost RGCs of patients. Compared with embryonic stem cells, induced
pluripotent stem cells (iPSCs) can be derived from adult somatic cells, and they are associated with fewer ethical
concerns and are less prone to immune rejection. In addition, patient-derived iPSCs may provide us with a cellular
model for studying the pathogenesis and potential therapeutic agents for optic atrophy.
Methods: In this study, iPSCs were obtained from patients carrying an OPA1 mutation (OPA1+/−-iPSC) that were
diagnosed with optic atrophy. These iPSCs were differentiated into putative RGCs, which were subsequently
characterized by using RGC-specific expression markers BRN3a and ISLET-1.
Results: Mutant OPA1+/−-iPSCs exhibited significantly more apoptosis and were unable to efficiently differentiate
into RGCs. However, with the addition of neural induction medium, Noggin, or estrogen, OPA1+/−-iPSC differentiation
into RGCs was promoted.
Conclusions: Our results suggest that apoptosis mediated by OPA1 mutations plays an important role in the
pathogenesis of optic atrophy, and both noggin and β-estrogen may represent potential therapeutic agents for
OPA1-related optic atrophy.
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Background
Autosomal dominant optic atrophy (DOA) is the most
common hereditary optic atrophy and is characterized by
central vision loss and degeneration of retinal ganglion
cells (RGCs). RGCs transmit visual information from pho-
toreceptors in the eye to several regions in the thalamus,
hypothalamus, and midbrain. The axons from RGCs also
form the optic nerve and extend to the optic chiasm and
visual cortex. The optic nerve is vulnerable to genetic and
environmental risks, and OPA1 mutations are the most
common cause of DOA. OPA1 is a nuclear gene that
encodes an inner mitochondrial membrane protein.
Mutations in OPA1, including missense, nonsense,
deletions/insertions, and splicing mutations, have resulted
in decreased ATP production, reduced mitochondrial
membrane potential, and mitochondrial dysfunction,
including mitochondrial fragmentation [1–3]. Some
OPA1 mutations have also resulted in truncated mutant
proteins and therefore haploinsufficiency is responsible
for certain clinical phenotypes. Unfortunately, a majority
of optic atrophy patients have experienced significant
RGC loss by the time of diagnosis. Therefore, cellular
therapy may be a promising treatment, especially given
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the advances that have been made in the use of human
embryonic stem cells (hESCs) and induced pluripotent
stem cells (iPSCs) [4–9].
iPSCs are derived from nonpluripotent adult cells
that have various genes and transcription factors in-
duced [10, 11]. As a result, iPSCs and hESCs share
many defining characteristics: they both express various
stem cell-specific markers, they maintain a self-renewal
capacity, and they can be differentiated into various cell
types. Correspondingly, when iPSCs are injected into
mouse blastocysts, viable chimeras have been gener-
ated. Although additional research is needed, iPSCs
have the potential to be a useful tool for drug screening
and disease modeling. In addition, the use of iPSCs for
cell therapy may facilitate transplantation approaches
that are associated with fewer ethical concerns and are
less prone to immune rejection compared with that of
hESCs.
The differentiation of iPSCs into RGCs is regulated by
many intrinsic and extrinsic factors, including those in-
volved in Notch signaling pathways [12, 13]. For ex-
ample, Notch signaling regulates the total number of
RGCs by lateral inhibition of the retina and prevents ret-
inal progenitor cells from differentiating. As a result,
retinal progenitor cell status is maintained and RGC
production is inhibited [14, 15]. Notch signaling is also
downregulated immediately before the differentiation of
retinal progenitor cells into RGCs. Therefore, inhibition
of Notch signaling may promote RGC production.
Recently, we developed a stepwise chemical protocol for
the differentiation of hESCs and normal iPSCs into func-
tional RGCs by using N-[N-(3, 5-difluorophenacetyl)-l-al-
anyl]-S-phenylglycine t-butyl ester (DAPT) [16]. In the
present study, we were able to generate human iPSCs
from fibroblast cells obtained from patients diagnosed
with optic atrophy and carrying an OPA1 mutation. The
goal of this study was to evaluate the potential for these
iPSCs to differentiate into RGCs. These studies also pro-
vide an opportunity to better understand the pathogenesis
of optic atrophy and to characterize a cellular model
that may be useful for drug screening. It was observed
that the mutant OPA1-derived iPSCs exhibited a signifi-
cant increase in apoptosis and were not able to be dif-
ferentiated into RGCs with treatment of DAPT.
However, in the presence of neural induction medium,
these OPA1+/−-iPSCs were able to be differentiated into
RGCs. Noggin was identified as the critical component
in this medium, and was also found to promote the dif-
ferentiation of OPA1+/−-iPSCs into RGCs. Similarly,
estrogen which was used to treat the patients with
Leber’s hereditary neuropathy was found to be able to
rescue OPA1+/−-iPSC differentiation. Under these condi-
tions, OPA1+/−-iPSCs with the treatment of DAPT devel-
oped elongated axons and displayed similar morphology
to that of control RGCs. Overall, these results demon-
strate that an RGC differentiation protocol with DAPT
treatment is able to efficiently induce the differentiation of
OPA1 mutant-derived iPSCs into RGCs in the presence of
neural induction medium, Noggin, or estrogen.
Methods
Generation and maintenance of iPSCs
The consent forms were signed by all patients involved
in this study before research initiation. The patients were
subjected to a protocol that was approved by the UC
Irvine and Cincinnati Children’s Medical Center IRB
committee. Teratoma formation assays were undertaken
with prior approval from the UC Irvine Animal Care
and Use Committee (IACUC No. 2008-2855). Briefly, to
obtain fibroblast cells, a needle punch biopsy of the skin
was performed for each patient, and the cells were cul-
tured as described previously [17]. Skin fibroblasts from
VO (abbreviated patient’s name) and OL (abbreviated
patient’s name) were then infected with a retrovirus ex-
pressing human transcription factors OCT4, SOX2, KLF4,
and c-MYC, as described previously [17]. Multiple iPSC
colonies were generated from each patient fibroblast cell
line (VO and OL) with mutation in OPA1 (OPA1 intron
24 c.2496 + 1 G > T, NM_015560.2), maintained and pas-
saged in a feeder-independent culture system mTeSR1/
Matrigel according to the manufacturer’s instructions
(Stemcell Technologies, Vancouver, BC, Canada). After
the iPSCs reached 80 % confluence, the medium was re-
moved and the cells were rinsed once with DMEM/F12.
Dispase (1 mg/mL, Life Technologies, Carlsbad, CA,
USA) was added to each well of the six-well plates, and
after 4–7 min incubation in 37 °C CO2 incubator until the
colony edge started to curl off, the dispase was removed
followed by two times wash with DMEM/F12 (Gibco,
Carlsbad, CA, USA), then 1 ml mTeSR1 medium was
added to each well of six-well plates. The cells were subse-
quently dissociated into small clamps with pipettes and
plated on matrigel-coated plates for further expanding or
maintenance. The control iPSCs were generated from skin
fibroblasts of a healthy 40-year-old female using the same
methods as those of VO and OL. Maintenance and subcul-
ture of the control iPSCs were using the same mTeSR1/
Matrigel culture system.
Differentiation of iPSCs
iPSCs were differentiated as described previously [16]
with modification. Briefly, embryoid bodies (EBs) were
formed by dissociating undifferentiated colonies with
1 mg/mL dispase and suspending the small cell aggregates
in six-well ultra-low attachment plates (Nunc, Thermal
Scientific, Odessa, TX, USA) in hESC medium without
basic fibroblast growth factor (bFGF) (DMEM/F12, knock-
out serum replacement, GlutaMax™-1, β-mercaptoethanol
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and Gibco MEM non-essential amino acids). On day 5,
the mature EBs were then transferred to gelatin-pretreated
plates and were cultured in hESC medium containing
10 % fetal bovine serum (FBS; Atlanta Biologicals, Atlanta,
GA, USA). Neural rosettes appeared after several days.
One week later, the neural rosettes were mechanically
lifted using a syringe needle and a pipette tip, then were
grown in suspension in RGC differentiation medium
containing hESC medium supplemented with 10 % FBS
and 10 μM DAPT (Sigma-Aldrich, St Louis, MO, USA)
for 5 days to facilitate the formation of neurospheres.
The neurospheres were then transferred onto poly-L-
ornithine/laminin-coated plates and RGC differentiation
medium containing fresh DAPT was provided every
other day. On days 24, 31 or 38 following the start of
differentiation, cells were fixed with 4 % paraformalde-
hyde (PFA) and were examined by immunofluorescence
(IF) staining. For some experiments, the culture medium
was supplemented with 10 % neural induction medium
(Stemcell Technologies, Vancouver, BC, Canada), 100 ng/
ml human recombinant Noggin (EMD Millipore, Billerica,
MA, USA), or 100 nM 17β-estradiol (Sigma-Aldrich, St
Louis, MO, USA).
Immunofluorescence
IF analysis was performed as previously described [16].
Briefly, cells were fixed with 4 % PFA for 10 min at room
temperature (RT), followed by two times wash with
phosphate-buffered saline (PBS). After incubation for
1 hour in blocking buffer composed of 10 % goat serum
(Life Technologies, Carlsbad, CA, USA) and 0.2 % Tri-
ton X-100 (Sigma-Aldrich, St Louis, MO, USA) in PBS,
samples were incubated with diluted primary antibodies
for 1 hour at RT. The following primary antibodies were
used: rabbit anti-human TUJ1 (1:100, Fitzgerald Indus-
trial Industries, Acton, MA, USA); mouse anti-human
BRN3a (1:50, Santa Cruz Biotechnology, Dallas, Texas,
USA); ISLET-1 (1:40, Developmental Studies Hybridoma
Bank - University of Iowa, Iowa City, Iowa, USA); ZO-1
(1:200, Life Technologies, Carlsbad, CA, USA); and
rabbit anti-human PAX6 (1:200, BioLegend, formerly
Covance Antibody Products Covance, San Diego, CA,
USA). The cells were then washed three times with 1×
PBS, 5 min each wash, and the samples were incubated
with secondary antibodies and DAPI (1:400 dilution,
Life Technologies, Carlsbad, CA, USA). The secondary
antibodies included goat anti-rabbit and goat anti-
mouse IgGs conjugated with Alexa Fluor 488 or Alexa
Fluor 594 (Life Technologies, Carlsbad, CA, USA), as
appropriate. After 1 hour at RT, the cells were washed
three times with 1× PBS, 5 min each wash, and visual-
ized with a fluorescence microscope (Zeiss, Axiovert
100 M,) and analyzed with Axiovision Rel.4.8 software
(Zeiss).
Statistical analysis
For each experiment, three replicates with different col-
onies were performed as previously described [16]. The
data are expressed as the mean ± standard deviation
(SD). Student’s t-test was used to compare between two




Fibroblasts collected from skin biopsies were cultured
and differentiated in vitro. Retroviral and Sendai infec-
tions were performed to induce the exogenous expres-
sion of human transcription factors OCT, SOX2, KLF4,
and c-MYC [10]. Both control and patient-derived iPSCs
(VO and OL, carrying mutation NM_015560.2(O-
PA1):c.2496 + 1G > T) grew into colonies and exhibited
a similar morphology. Immunostaining assays further
demonstrated that VO-iPSCs expressed the stem cell-
specific markers NANOG and SSEA-4 (Fig. 1a, data
from OL-iPSCs not shown). In teratoma formation as-
says, the in vivo pluripotency of the derived-iPSC col-
onies were confirmed (Fig. 1b, data from OL-iPSCs not
shown). Lastly, DNA sequencing of the VO-iPSCs
proved that the original patient-specific mutation of the
OPA1 gene was maintained (Fig. 1c, data from OL-
iPSCs not shown). Our results suggested that we suc-
cessfully generated bona fide VO-iPSCs, which have the
potential to differentiate into lineages of three germ
layers.
Mutation of OPA1 causes increased apoptosis in OPA1
+/−-iPSCs
After the patient iPSC lines (mutant OPA1-iPSC) were
generated and established, a large number of dead VO-
iPSCs were observed during daily media changes com-
pared to the control iPSCs. Although the function(s) of
OPA1 are not fully understood, it has been shown to
play an important role in mitochondrial fusion, apop-
tosis, ATP production, and reactive oxygen species pro-
duction. Accumulating evidence further suggests that
OPA1 may be a target for mitochondrial apoptotic effec-
tors, and abnormal apoptosis leads to RGC death that is
observed in DOA patients [18]. In Hela cells, downregu-
lation of OPA1 by RNAi led to mitochondrial fragmenta-
tion, cytochrome-c release, and apoptosis [18]. Thus,
OPA1 appears to play an important role in regulating
apoptosis. To investigate whether OPA1 mutations are
responsible for the increase in apoptosis observed for
the OPA1+/−-iPSC lines, the control and VO-iPSCs were
assayed for necrosis and apoptosis using an Apoptotic
Kit (Invitrogen, Carlsbad, CA, USA), with the combin-
ation of YO-PRO-1 dye and propidium iodide providing
a sensitive indicator for these two cell types, respectively
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[19]. Compared with the control iPSCs, the OPA1-mutant
VO-iPSCs exhibited a 1.5-fold and 2-fold increase in
the number of apoptotic and necrotic cells, respect-
ively (p < 0.05 in each case) (Fig. 2).
OPA1+/−-iPSCs do not differentiate into neural rosettes in
vitro
Using a recently developed chemical stepwise protocol
for the differentiation of hESCs and iPSCs into func-
tional RGCs [16], normal control iPSCs were differenti-
ated into neural rosettes (PAX6+/RX+) and then were
cultured with the Notch inhibitor DAPT. After 3 weeks
of DAPT treatment, a high percentage of cells were
found to express the neuronal marker TUJ1, as well the
RGC markers BRN3A, BRN3B, ATOH7, γ-Synuclein,
ISLET-1, and THY-1 [16]. The differentiated RGCs add-
itionally generated action potentials, as well as spontan-
eous and evoked excitatory post-synaptic currents. These
data demonstrate that PAX6+/RX+ neural cells derived
from hESCs and iPSCs could be differentiated into func-
tional RGCs.
To determine whether OPA1 mutations affect the dif-
ferentiation of iPSCs into RGCs, the control, VO- and
OL-iPSC aggregates were cultured with hESC medium
without bFGF for 5 days. EBs derived from VO-iPSCs
displayed irregular shapes and unsmoothed edges com-
pared with the EBs derived from the control iPSCs
(Fig. 3a). However, OL-EBs exhibited similar morph-
ology to that of controls (Additional file 1: Figure S1A).
Following the differentiation of these EBs (see Methods),
the presence of neural rosettes was characterized with IF
staining of tight junction protein ZO-1 [20]. While the
control iPSCs were able to differentiate into neural ro-
settes that exhibited apical localization of ZO-1 (Fig. 3b
and c, left panel), very few neural rosettes formed were
derived from the VO- and OL-iPSCs (Fig. 3b and c, right
panel; Additional file 1: Figure S1B, right panel). These




















Fig. 1 Characterization of iPSCs obtained from patient’s skin cells carrying an OPA1 mutation. a Control and VO-iPSCs (patient-derived) were stained
with antibodies against pluripotency cell surface markers SSEA4 (red) and transcriptional factor Nanog (green). DAPI staining of nuclei is shown in blue.
Scale bars = 20 μM. b Hematoxylin and eosin staining of VO-iPSC-derived teratomas shows cell lineages derived from three germ layers, the ectoderm
(neuron, skin), mesoderm (blood vessel, bone), and endoderm (gland). A gross observation of dissected teratomas is also shown (left, kidney capsule;
right, testis). c A representative sequencing trace that confirmed the presence of an OPA1 mutation (NM_015560.2(OPA1):c.2496 + 1G > T) in a
VO-iPSC line
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efficiently differentiated into neural cells under these
culture conditions.
Neural rosettes derived from OPA1+/−-iPSCs were not able
to differentiate into RGCs
Although the VO- and OL-iPSCs were not efficiently dif-
ferentiated into neural cells, a few neural rosette-like
structures were still obtained. To determine whether
these VO- and OL-neural rosettes can be differentiated
into RGCs, the rosettes were incubated and differenti-
ated with the RGC differentiation medium. Putative
RGCs derived from the control, VO- and OL-iPSCs were
fixed with 4 % PFA on day 24 or on day 38, followed by
IF staining of two RGC markers (POU-domain tran-
scription factor BRN3a, and LIM-HD transcriptional
factor ISLET-1). BRN3a is expressed in RGCs that in-
nervate the retinal-hypothalmic/retinal-colicular path-
way, and has previously been shown to be a marker for
RGCs [21]. In an ISLET-1 conditional knockout mouse,
a significant loss of RGCs due to apoptosis was ob-
served, yet RGC generation was unaffected. These re-
sults suggest that ISLET-1 plays an essential role in RGC
survival [22]. Previous IF analyses also detected co-
localization of BRN3b and ISLET-1 in differentiating
RGCs [22]. BRN3b is largely co-expressed with BRN3a
in the mouse embryonic retina, and BRN3a and BRN3b
have been shown to share redundant functions [23].
Therefore, BRN3a and ISLET-1 are recognized as RGC
markers. In addition, TUJ-1 is a human β-tubulin III
protein that is expressed in neurons, particularly in
neural progenitor cells, and is widely used as a marker
for neural differentiation [24, 25]. As shown in Fig. 4a
and b, differentiated cells derived from the control, VO-
and OL-iPSCs on day 24 were found strongly expressing
TUJ-1 in both axons and body neurons. However, ex-










Fig. 2 Mutation of OPA1 increases necrosis and apoptosis in iPSCs. a, b Control and VO-iPSCs were stained with propidium iodide and YO-PRO-1
dye using an Apoptotic kit (Invitrogen) to detect necrotic cells (red, left panels) and apoptotic cells (green, right panels), respectively. Scale bars = 100 μM.
c Each column represents the number (mean counts) of either necrotic or apoptotic cells from control and VO-iPSCs. The number of necrotic and
apoptotic VO-iPSCs was significantly higher compared to that of the control iPSCs. The values shown are given as mean ± SD (*p < 0.05, **p < 0.001).
SD is shown inside the boxes. iPS induced pluripotent stem
Chen et al. Stem Cell Research & Therapy  (2016) 7:2 Page 5 of 14
differentiated neuron cells derived from the control
iPSCs (Fig. 4a and b, upper panels), and not in neuron
cells derived from VO- and OL-iPSCs (Fig. 4a and b,
lower panels; Additional file 1: Figure S2).
To determine whether a longer cell culture period
would promote OPA1+/−-RGC development, cells were
cultured for an additional 2 weeks up to day 38. It was
observed that the cells detached more readily from the
bottoms of the wells, and IF analysis showed that neuron
cells derived from both the control iPSCs and VO-iPSCs
exhibited positive TUJ1 staining (Additional file 1:
Figure S3). In contrast, expression of BRN3a and
ISLET-1 was not detected in neuron cells derived from
VO-iPSCs (Additional file 1: Figure S3A and B, lower
panels), yet expression of these two proteins was de-
tected in neuron cells derived from the control iPSCs
(Additional file 1: Figure S3A and B, upper panels). In
combination, these results suggest that VO- and OL-
iPSCs are not able to differentiate into RGCs following
treatment with 10 μM DAPT and 10 % FBS, thereby
implying that these cells may require additional re-
agents or growth factors to counteract the effect(s) of
OPA1 mutations in order to gain the capacity of differ-
entiation into RGCs.
Neural induction medium promotes OPA1+/−-iPSC
differentiation into RGCs
Since VO-iPSCs were not successfully differentiated into
RGCs using a previously published protocol [16], modifi-
cations of the culture conditions were tested. First, the
differentiation medium was changed from hESC
medium supplemented with 10 % FBS to hESC medium
supplemented with both 10 % FBS and 10 % neural in-
duction medium. As a result, the efficiency of EB differ-
entiation of VO-iPSCs into neural rosettes increased
3.89-fold (Fig. 5a). In contrast, the efficiency of the con-
trol iPSC differentiation into neural rosettes did not sig-
nificantly differ under two culture conditions (Fig. 5a).










Fig. 3 OPA1+/−-iPSCs are unable to differentiate into neural rosettes (NR). Embryoid bodies (EBs) were cultured with hESC medium
(without bFGF) on ultra-low attachment plates. Day 5 Ebs derived from the control iPSCs were shown in (a) (left panel). EBs were well
organized and exhibited a round shape. In contrast, EBs derived from VO-iPSCs (a, right panel) exhibited irregular edges and did not
have a round shape. EBs were subsequently plated onto PLO/L-coated wells and were cultured with hESC medium containing 10 %
FBS. b Cells were imaged 5 days after EB attachment. c IF staining with a ZO-1 antibody (green) was used to show neural rosette
structures. Scale bars = 20 μM
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neural rosettes from each group, both sets were positive
for both Pax6 and ZO-1 (Fig. 5b and c).
To determine if these neural rosettes could be differ-
entiated into RGCs, the previously published protocol
was modified as follows. Briefly, mature EBs on day 6
were plated on cell culture plates coated with PLO/L,
and were cultured in hESC/10 % FBS/10 % neural in-
duction medium. After 1 week, neural rosettes were
mechanically transferred to Nunc ultra-low attachment
plates and were cultured as floating neuron spheres
with the same differentiation medium, except 10 μM
DAPT was added. After 5 days, the neurospheres were
collected and plated on PLO/L-coated wells for RGC
differentiation with the same DAPT-containing differ-
entiation medium. On day 31, putative RGCs were fixed
with 4 % PFA, followed by IF staining against TUJ1,
BRN3a, and ISLET-1. The neural cells that derived
from the VO-, OL- and control iPSCs were positive for
both BRN3a and ISLET-1 (Fig. 6a and b; Additional file
1: Figure S4). Next, the efficiency of RGC differenti-
ation was quantified using the ratio of RGC-positive
signal versus DAPT signal (Additional file 1: Figure S5).
The differentiation efficiency between VO-iPSCs and
the control iPSCs to RGCs was found to be very similar
(p = 0.076 and p = 0.084 for ISLET-1 and BRN3a,
respectively).
Noggin promotes the differentiation of OPA1+/−-iPSCs
into neural stem cells
Noggin is a secreted signaling molecule that plays an
important role in regulating several signaling pathways
during animal development. In Xenopus, Noggin-
treated pluripotent cells were found to be able to dif-
ferentiate into a multipotent retinal progenitor lineage,
which facilitated functional eye formation following
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TUJ-1 ISLET-1 TUJ-1 / ISLET-1 / DAPI
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Fig. 4 OPA1+/−-iPSCs failed to differentiate into RGCs with culture medium supplemented with 10 % FBS and DAPT. Neurospheres were plated
onto PLO/L-coated plates and cultured in hESC medium containing 10 μM DAPT and 10 % FBS for 7 days before fixation with 4 % PFA on day
24. Cells were stained with TUJ1 (red), BRN3a (green, a) and ISLET-1 (green, b) antibodies. Scale bars = 20 μM
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colleagues also reported that a high-dose treatment of
Noggin promoted retinal cell differentiation in Xen-
opus embryonic stem cells [27]. During the differenti-
ation of mouse iPSCs, the addition of Noggin and
fibroblast growth factor 2 into the differentiation
medium for a short period of time resulted in a signifi-
cant enhancement of retinal progenitor cell growth
[28]. To evaluate the potential of Noggin to induce the
differentiation of human iPSCs into neural retinal cells,
especially patient-derived iPSCs containing mutations,
a revised protocol was tested. Briefly, mature EBs on
day 6 were plated on laminin-coated plates and cul-
tured in hESC medium containing 10 % FBS and
100 ng/mL Noggin. After 7 days, the cells were cul-
tured as floating neural spheres in RGC differentiation
medium containing hESC medium, 10 % FBS, 10uM
DAPT, and 100 ng/mL Noggin. After 5 days, the neuro-
spheres were plated on PLO/L-coated plates and differ-
entiated for another 14 days. On day 31, putative RGCs
were fixed in 4 % PFA and IF analysis detected robust
expression of BRN3a and ISLET-1 in the neuron cells
derived from VO- and OL-iPSCs (Fig. 7a and b; Add-
itional file 1: Figure S6). Similar expression patterns
were observed for the RGCs derived from the control
iPSCs (Fig. 7a and b).
To examine the function of Noggin during RGC differ-
entiation, two separate, yet parallel, experiments were per-
formed at the same time. In the first experiment, iPSCs
were treated with Noggin during the differentiation stage
of neural rosettes. However, the subsequent culture steps
did not include Noggin. In the second experiment, Noggin
was present in the RGC differentiation medium and was
not present in the medium used to culture the neural ro-
settes. VO neuron cells in the first experiment exhibited
robust expression of BRN3a and ISLET-1 (Fig. 8). How-
ever, in the second experiment, very few neural rosettes
were available for differentiation, and IF staining showed
very sparse expression of BRN3a and ISLET-1 (data
not shown). Based on the results of these two experi-
ments, it appears that Noggin promotes the formation
A
Control + VO +
ZO-1/Pax6/DAPI
B C
Control Control + VO VO +
Fig. 5 Control and VO-iPSCs were cultured in hESC medium containing 10 % FBS with and without 10 % NIM. Neural rosettes (NR) were stained
with ZO-1 (green) and Pax6 (red) antibodies. In panel a, with (Control+ and V0+) and without (control & V0)10 % NIM Embryoid bodies (EBs) that
exhibited a typical “rosette” structure were counted. Student’s t-test was used to analyze the data. All samples were normalized to the control
values. *p < 0.01. Scale bars = 20 μM. Representative images are shown in panels b and c
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of neural stem cells (neural rosettes), and does not in-
duce RGC differentiation during the process of VO-iPSC
differentiation.
17β-estradiol promotes OPA1+/−-iPSC differentiation into
RGCs
In a cybrid cell model of Leber’s hereditary optic neur-
opathy (LHON) involving the selective loss of RGCs,
treatment with 17β-estradiol was found to signifi-
cantly decrease levels of apoptosis, to increase cell
viability, and to enhance mitochondrial biogenesis
[29]. In addition, immune-peroxidase staining con-
firmed that estrogen receptor-β is located on the
mitochondria of human RGCs, thereby implying that
estrogen mediates its function via this receptor [29].
Since VO-iPSCs exhibited significant apoptosis, and
17β-estradiol has proved to be an inhibitor of apop-
tosis, the cell culture medium used for iPSC differen-
tiation was supplemented with 100 nM 17β-estradiol.
When VO- and OL-iPSCs were stained with
antibodies specific for detection of BRN3a and ISLET-
1, both proteins were found to be highly expressed by
neuron cells derived from VO- and OL-iPSCs on day
31 (Fig. 9; Additional file 1: Figure S7), similar to the
RGCs derived from the control iPSCs (data not
shown). Taken together, these results indicate that
17β-estradiol can promote RGC development possibly
through inhibition of apoptosis, and thus may serve as
a potential therapeutic agent for OPA1 mutation-
related optic atrophy.
Discussion
RGC loss is critical for the development of optic atro-
phy, LHON, and glaucoma [30–32]. Moreover, there is
currently no effective treatment for this group of
diseases. Therefore, cell replacement may represent a
potential therapy for lost neurons [20, 33]. Although
hESCs have been used to generate neural retinal precur-
sors [34], there are ethical considerations associated with
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Fig. 6 Neuron induction medium (NIM) promoted OPA1+/−-RGC generation detected by IF. Neurospheres derived from the control and VO-iPSCs
in the presence of NIM were plated onto PLO/L-coated plates and were cultured with hESC medium containing 10 μM DAPT, 10 % FBS, and
10 % NIM for 14 days. Cells were fixed with 4 % PFA on day 31. a TUJ1 (green) and BRN3a (red) staining are shown. b TUJ1 (green) and ISLET1
(red) staining are shown. Scale bars = 20 μM
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rejection [35]. iPSC technology circumvents these issues
since patient-specific iPSCs can be generated, and these
iPSCs have the ability to differentiate into various cell
types [23, 36, 37].
It has also been reported recently that retinal ganglion-
like cells can be generated from iPSCs [28, 38–40]. Several
protocols have been developed and published for the
retina-specific differentiation of stem cells. These proto-
cols employ non-adherent culturing of cells to induce
neurosphere formation, and the cells are subsequently dif-
ferentiated into retinal progenitor epithelial cells and
neural epithelial rosette-containing colonies. Using this
system, early retinal development from hESCs and iPSCs
has been modeled [41].
To promote the differentiation of retinal progenitor
cells into ganglion cells, we recently developed a proto-
col that included the Notch antagonist DAPT [16].
Using this rather straightforward protocol, lineage
differentiation to obtain RGCs was significantly en-
hanced. This result also suggests that Notch signaling
plays an important role in stem cell differentiation, and
may have a clinical application. When iPSCs harboring
OPA1 mutations were evaluated, increased apoptosis
was observed. However, in the presence of neural induc-
tion medium, these iPSCs were still able to differentiate
into RGCs. Taken together, these results suggest that the
primary pathogenesis of optic atrophy due to an OPA1
mutation is most likely due to a reduced number of
RGCs, secondary to increased levels of RGC apoptosis.
Noggin is the major component of neural induction
medium, and as a potent inhibitor of BMP enhances
eye field differentiation [42]. In transgenic mice over-
expressing Noggin, apoptosis of the developing eyelid
epithelium was found to be inhibited via the BMP-
Smad pathway [43]. IF analysis and in situ
hybridization of proteins and receptors involved in the
A


















Fig. 7 Noggin rescued OPA1+/−-iPSC differentiation into RGCs confirmed by IF. Mature EBs were cultured with 100 ng/mL Noggin to obtain
putative RGCs. Cells were fixed with 4 % PFA on day 31. a TUJ-1 (green) and BRN3a (red) staining are shown. b TUJ-1 (green) and ISLET1 (red)
staining are shown. Scale bars = 50 μM in panel (a) and 100 μM in panel (b)
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BMP pathway also confirmed these results. It has been
shown in a hippocampal neurodegeneration animal
model that neuropeptide Y promotes neuroprotection
and enhances endogenous neurogenesis by enhancing
expression of Noggin [44]. These findings correlate
with our results showing that Noggin played an important
role in promoting generation of neuron stem cells, and
thus led to a success in OPA1+/−-iPSC differentiation into
RGCs (Fig. 7a and b and Fig. 8). Our results from two sep-
arate, yet parallel experiments showed that Noggin signifi-
cantly enhanced neuron rosette formation, and thus
promoted OPA1+/−-RGC generation. However, the de-
tailed molecular mechanism by which Noggin affects
OPA1+/−-RGC differentiation is yet to be elucidated. The
effectiveness of Noggin was replicable. Without adding
Noggin in the differentiation medium, very few neuron ro-
settes formed and were not able to further differentiate
into RGCs. Noggin mutations in mouse embryos have
been associated with a significant increase in neural crest
cell apoptosis [45], indicating that Noggin plays an im-
portant role in regulating apoptosis during neural crest
development. Based on the results of the present study,
we further hypothesize that Noggin can partially reverse
the differentiation defects mediated by OPA1 mutations.
17β-estradiol is a potent steroid hormone and plays an
important protective role in many organ systems in
addition to the reproductive system. 17β-estradiol has
also been shown to function as a neuromodulator and
neuroprotectant by manipulating various molecular
pathways [46]. For example, using a hippocampal slice
culture model, treatment with estrogen in vitro has been
shown to inactivate the cell death mediator, GSK-3β, via
phosphorylation [47]. As a result, neuron viability and
survival were promoted, and estrogen treatment was
identified as a promising approach for preventing cell
death. In an in vivo mouse model of glaucoma, a signifi-
cant loss of RGCs was observed [48]. However, treat-
ment with 17β-estradiol was found to prevent RGC
apoptosis, and RGC neurofiber integrity was protected
[48]. Given that estrogen receptor-β is located in the
ganglion cell layer [49], it is very likely that estrogen
plays an important role in preventing RGC loss and pro-
moting RGC development through interaction with es-
trogen receptor-β. Accordingly, the present results show
that RGCs were generated from VO- and OL-iPSCs after
addition of estrogen into the RGC differentiation
medium. Thus, it appears that estrogen can counteract
the effects mediated by mutated OPA1 proteins in terms
of apoptosis inhibition.
The molecular mechanism(s) by which OPA1 muta-
tions lead to increased apoptosis are not completely
understood, and remain controversial. It has been shown
that inhibition of the mitochondrial fission machinery
and upregulation of mitochondrial fusion can both regu-
late cell death, and OPA1 is an important regulator of
mitochondrial fusion. However, OPA1 protects cells
from apoptosis by preventing cytochrome-c release,
which can occur independently from mitochondrial fu-
sion. OPA1 also controls the shape of mitochondrial
cristae by maintaining tight junctions during apoptosis
that is induced by oligomerization of OPA1. Conversely,
BCL-2 can widen cristae junctions and disrupt OPA1
TUJ-1 BRN3a TUJ-1/ BRN3a/ DAPI





Fig. 8 Noggin treatment only during OPA1+/−-iPSC differentiation into neural rosettes could rescue OPA1+/−-RGC generation. Control and
VO-iPSCs were incubated with 100 ng/mL Noggin in the cell culture medium only during the differentiation of neural rosettes and
Noggin was removed in afterward differentation. Cells were fixed with 4 % PFA on day 31. Upper panel, TUJ1 (green) and BRN3a (red)
staining are shown. Lower panel, TUJ1 (green) and ISLET-1 (red) staining are shown. Scale bars = 100 μM. Data from the control under the
same treatment are not shown
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oligomers. Thus, the anti-apoptosis function of OPA1 is
distinct from its role in mitochondrial fusion, yet is not
distinct from its role in cristae remodeling [50]. It is an-
ticipated that further study of this dynamic protein may
identify additional novel therapies as well.
Conclusions
Recently, we have developed a straightforward protocol
to differentiate iPSCs into functional RGCs in which
neural rosettes were cultured in the presence of the
Notch inhibitor DAPT. Using this protocol, here we
show that OPA1 mutations cause a significant increase
in apoptosis in iPSCs, and iPSCs harboring OPA1 muta-
tion were unable to differentiate into RGCs. However,
both noggin and β-estrogen can rescue this phenotype,
suggesting apoptosis mediated by OPA1 mutations plays
an important role in the pathogenesis of optic atrophy,
and noggin and β-estrogen could be potential therapeutic
agents. These results will further our understanding of
how OPA1 mutations lead to RGC loss and optic atrophy.
Additional file
Additional file 1: Figure S1. OPA1+/−-iPSCs (OL) are unfavorable to
differentiate into neural rosette. Culture conditions were the same as
those in Fig. 3. Panel A shows day 5 EBs, which were derived from
control and OL-iPSCs, respectively. Morphologically, OL-EBs look similar to
control EBs. Panel B shows neuron rosettes (NRs) after 5 days of EB at-
tachment. Fewer and smaller neuron rosettes were derived from OL-EBs,
compared with neuron rosettes from control EBs. Figure S2 OPA1+/−-iPSCs
(OL) failed to differentiate into RGCs with culture medium supplemented
with 10 % FBS and DAPT. Differentiation method in Fig. 4 was followed.
Putative RGCs were fixed on day 24 before fixation, followed by IF
staining. Upper panel shows staining of TUJ1 (green) and BRN3a (red),
while lower panel displays staining of TUJ1 (green) and ISLET1 (red). The
scale bars equal 50 μM. Figure S3 IF analysis of RGCs derived from the
A


















Fig. 9 Addition of 17β-estradiol in RGC differentiation medium promoted generation of OPA1+/−-RGCs. Control and VO RGCs were incubated with
100 nM 17β-estradiol in the cell culture medium during all of the differentiation stages, including iPSC culturing. Putative RGCs were then fixed
with 4 % PFA on day 31. a TUJ1 (green) and BRN3a (red) staining are shown. b TUJ1 (green) and ISLET-1 (red) staining are shown. Scale bars = 50 μM in
panel (a) and 100 μM in panel (b)
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control and VO-iPSCs on day 38. Neurospheres were plated onto PLO/L-
coated plates and cultured in hESC medium containing 10 μM DAPT and
10 % FBS for 21 days before fixation with 4 % PFA on day 38. Cells were
stained with TUJ1 (green), BRN3a (red) and ISLET-1 (red) antibodies. The
scale bars equal 20 μM. Figure S4 NIM promoted OPA1+/−-RGC (OL)
generation detected by IF. Putative OL-RGCs derived from OL-iPSCs were
cultured with hESC medium containing 10 μM DAPT, 10 % FBS, and 10 %
neural induction medium (NIM) for 14 days before fixation on day 31.
Upper panel shows TUJ1 (green) and BRN3a (red) staining. Lower panel
shows staining of TUJ1 (green) and ISLET1 (red). The scale bars equal
50 μM. Figure S5 Quantification of RGC differentiation efficiency. The
culture medium used for RGC differentiation contained 10 % neural
induction medium. Samples were normalized to the control BRN3a/DAPI
staining or the control ISLET-1/DAPI staining. The number of BRN3a or
ISLET-1 signals versus the number of DAPI signals was calculated. A p-value
of 0.084 was obtained for the BRN3a signal comparison between the control
and VO, and a p-value of 0.076 was obtained for the ISLET-1 signal
comparison between the control and VO. Student’s t-test was used to
analyze differences between two groups. Figure S6 Noggin rescued
OPA1+/−-iPSC (OL) differentiation into RGCs confirmed by IF. Mature EBs
were cultured with hES medium containing 10 % FBS and 100 ng/mL
Noggin to obtain neuron rosettes, followed by culturing putative RGCs
with hES medium containing 10 % FBS, DAPT and 100 ng/mL Noggin.
Cells were fixed with 4 % PFA on day 31. Upper panel shows IF staining
of TUJ-1 (green) and BRN3a (red), whereas lower panel shows staining
of TUJ-1 (green) and ISLET1 (red). The scale bars equal 50 μM in both
panels. Figure S7 Addition of 17β-estradiol in RGC differentiation
medium promoted generation of OPA1+/−-RGCs (OL). Putative RGCs
were incubated with 100 nM 17β-estradiol in the cell culture medium
during all of the differentiation stages, followed by fixation on day 31.
Upper panel shows IF staining against TUJ1 (green) and BRN3a (red).
Lower panel shows TUJ1 (green) and ISLET-1 (red) staining. The scale
bars equal 50 μM. (PPTX 12904 kb)
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